Real outcomes from
real IP clinics

Context

Hope Therapeutics operates one of the largest interventional psychiatry clinic networks in the US, offering TMS and Spravato programs across multiple locations. With high patient volume and a sophisticated clinical team, they needed a monitoring solution that could scale across sites without adding staff overhead.

Challenge

Managing between-visit monitoring for hundreds of TRD patients across multiple clinic locations. PHQ-9 completion rates were consistently below 35%, leaving most patients with no objective monitoring between sessions.

Solution

Full deployment of Emobot passive monitoring across the Hope Therapeutics IP clinic network. EmoDTx enrolled at first visit; clinical teams access a unified dashboard at portal.emobothealth.com.

Context

Radial Health is one of the pioneering voices in interventional psychiatry in the US, co-founded by Dr. Carlene MacMillan, MD, FCTMSS and Dr. Owen Muir, MD, both now Medical Advisors to Emobot. Their flagship Bryant Park clinic runs a high-volume TMS and Spravato program and they are expanding across 6 states. Their clinical team ran the first US deployment of Emobot at scale.

Challenge

Radial Health's thesis is simple: interventional psychiatry only works at scale if the between-visit data problem is solved. Their providers wanted continuous, objective insight into how patients were doing between sessions (without adding friction for staff or patients), and they wanted something they could stand behind clinically across a multi-site network.

Solution

Full Emobot deployment across the Radial Health TMS and Spravato population starting September 2025. Patients enrolled in EmoDTx at first visit; clinicians access the dashboard at portal.emobothealth.com. The entire Radial Health staff (intake, clinicians, program managers) use Emobot as a core part of the workflow and actively refer peer IP clinics into the platform.

Context

A physician-owned TMS clinic treating 80+ active TRD patients per month. The clinic director had noticed a pattern: patients who responded well to acute TMS were dropping out of maintenance at high rates, and the clinic had no visibility into why until they were already gone.

Challenge

High maintenance phase dropout. Of patients completing acute TMS with a clinical response, nearly 40% did not return for maintenance, and the clinic had no early warning system to intervene before dropout occurred.

Solution

Emobot deployment at the end of acute treatment phase, with all responding patients enrolled in EmoDTx before leaving the clinic. Passive monitoring continues through maintenance with alert notifications to the clinical coordinator.

Context

A multi-provider practice with a dedicated Spravato program serving 50+ active patients. The practice had invested heavily in the REMS certification and infrastructure but was struggling with a clinical blind spot: what happened to patients in the 166 hours between their 2-hour REMS monitoring windows.

Challenge

No visibility into between-session Spravato response durability. Patients reporting 'fine' at sessions showed dramatically different trajectories when actual data became available; some were experiencing strong between-session decay that was invisible without continuous monitoring.

Solution

Emobot passive monitoring deployed at Spravato induction start. The depression index provided daily resolution across both induction and maintenance phases, enabling the clinical team to identify between-session decay patterns and adjust dosing protocols accordingly.